临床肿瘤学杂志
臨床腫瘤學雜誌
림상종류학잡지
CHINESE CLINICAL ONCOLOGY
2014年
10期
891-895
,共5页
祝鹏%刘慧颖%金凯舟%胡志前%王伟军
祝鵬%劉慧穎%金凱舟%鬍誌前%王偉軍
축붕%류혜영%금개주%호지전%왕위군
胰腺癌%黏蛋白4%胰腺导管腺癌%胰腺上皮内瘤变%免疫组织化学%预后
胰腺癌%黏蛋白4%胰腺導管腺癌%胰腺上皮內瘤變%免疫組織化學%預後
이선암%점단백4%이선도관선암%이선상피내류변%면역조직화학%예후
Pancreatic cancer%Mucin 4 ( MUC4)%Pancreatic ductal adenocarcinoma( PDAC)%Pancreatic intraepi-thelial neoplasias( PanINs)%Immunohistochemistry%Prognosis
目的:探讨黏蛋白4( MUC4)在胰腺上皮内瘤变( PanINs)和胰腺导管腺癌( PDAC)中的表达及临床意义。方法收集2009年3月1日至2011年12月31日第二军医大学附属长征医院的胰腺组织蜡块标本共85例。采用免疫组化SP法检测MUC4在48例正常胰腺导管(NP)、17例PanINs及20例PDAC组织中的表达情况。分析MUC4的表达与PDAC临床病理特征及预后的关系。结果 MUC4在NP组织中不表达;随着胰腺组织异型程度的增加,MUC4的表达逐渐增强;MUC4在NP、PanIN-1、PanIN-2、PanIN-3及PDAC组织中的阳性表达率分别为0、17.4%、52.6%、84.6%和90.0%;免疫组化评分分别为0、1.30±0.89、2.58±1.76、4.54±1.64和7.68±2.34,组间比较差异有统计学意义( P<0.001)。 MUC4在PDAC组织中的表达与神经浸润( P=0.028)、淋巴结转移( P=0.020)和CA19-9( P=0.028)有关。20例PDAC患者的中位总生存时间为17.0个月(95%CI:14.809~19.191个月);MUC4高表达者(免疫组化评分≥8.8分)为13.0个月(95%CI:7.456~18.544个月), MUC4低表达者(免疫组化评分<8.8分)为20.0个月(95%CI:15.521~24.479个月),差异有统计学意义( P=0.003)。结论MUC4可能参与了PDAC的发生、发展,其表达升高可能是PDAC演进的早期事件,MUC4高表达可能对PDAC的浸润和转移均有影响并提示预后不良。
目的:探討黏蛋白4( MUC4)在胰腺上皮內瘤變( PanINs)和胰腺導管腺癌( PDAC)中的錶達及臨床意義。方法收集2009年3月1日至2011年12月31日第二軍醫大學附屬長徵醫院的胰腺組織蠟塊標本共85例。採用免疫組化SP法檢測MUC4在48例正常胰腺導管(NP)、17例PanINs及20例PDAC組織中的錶達情況。分析MUC4的錶達與PDAC臨床病理特徵及預後的關繫。結果 MUC4在NP組織中不錶達;隨著胰腺組織異型程度的增加,MUC4的錶達逐漸增彊;MUC4在NP、PanIN-1、PanIN-2、PanIN-3及PDAC組織中的暘性錶達率分彆為0、17.4%、52.6%、84.6%和90.0%;免疫組化評分分彆為0、1.30±0.89、2.58±1.76、4.54±1.64和7.68±2.34,組間比較差異有統計學意義( P<0.001)。 MUC4在PDAC組織中的錶達與神經浸潤( P=0.028)、淋巴結轉移( P=0.020)和CA19-9( P=0.028)有關。20例PDAC患者的中位總生存時間為17.0箇月(95%CI:14.809~19.191箇月);MUC4高錶達者(免疫組化評分≥8.8分)為13.0箇月(95%CI:7.456~18.544箇月), MUC4低錶達者(免疫組化評分<8.8分)為20.0箇月(95%CI:15.521~24.479箇月),差異有統計學意義( P=0.003)。結論MUC4可能參與瞭PDAC的髮生、髮展,其錶達升高可能是PDAC縯進的早期事件,MUC4高錶達可能對PDAC的浸潤和轉移均有影響併提示預後不良。
목적:탐토점단백4( MUC4)재이선상피내류변( PanINs)화이선도관선암( PDAC)중적표체급림상의의。방법수집2009년3월1일지2011년12월31일제이군의대학부속장정의원적이선조직사괴표본공85례。채용면역조화SP법검측MUC4재48례정상이선도관(NP)、17례PanINs급20례PDAC조직중적표체정황。분석MUC4적표체여PDAC림상병리특정급예후적관계。결과 MUC4재NP조직중불표체;수착이선조직이형정도적증가,MUC4적표체축점증강;MUC4재NP、PanIN-1、PanIN-2、PanIN-3급PDAC조직중적양성표체솔분별위0、17.4%、52.6%、84.6%화90.0%;면역조화평분분별위0、1.30±0.89、2.58±1.76、4.54±1.64화7.68±2.34,조간비교차이유통계학의의( P<0.001)。 MUC4재PDAC조직중적표체여신경침윤( P=0.028)、림파결전이( P=0.020)화CA19-9( P=0.028)유관。20례PDAC환자적중위총생존시간위17.0개월(95%CI:14.809~19.191개월);MUC4고표체자(면역조화평분≥8.8분)위13.0개월(95%CI:7.456~18.544개월), MUC4저표체자(면역조화평분<8.8분)위20.0개월(95%CI:15.521~24.479개월),차이유통계학의의( P=0.003)。결론MUC4가능삼여료PDAC적발생、발전,기표체승고가능시PDAC연진적조기사건,MUC4고표체가능대PDAC적침윤화전이균유영향병제시예후불량。
Objective To analyze the differential expression and clinical significance of mucin 4 ( MUC4) in pancreatic in-traepithelial neoplasias (PanINs) and pancreatic ductal adenocarcinoma (PDAC). Methods We collected 85 cases of paraffin of pancreatic tissue specimens from Affiliated Changzheng Hospital of the Second Military Medical University from 2009-03-01 to 2011-12-31. Immunohistochemical SP method was used to examine the expression of MUC4 in 48 normal pancreatic duct (NP) tissues, 17 Pan-INs tissues and 20 PDAC tissues. The correlation of MUC4 expression with clinicopathological characteristics and prognosis of PDAC patients was analyzed. Results MUC4 was not expressed in NP;MUC4 expression gradually increased with the progression of pancre-atic tissue. The positive expression rates of MUC4 in NP, PanIN-1, PanIN-2, PanIN-3 and PDAC were 0, 17. 4%, 52. 6%, 84. 6%and 90. 0%, respectively; The immunohistochemical scores of MUC4 expression in NP, PanIN-1, PanIN-2, PanIN-3 and PDAC groups were 0, 1. 30±0. 89, 2. 58±1. 76, 4. 54±1. 64 and 7. 68±2. 34, with statistic significance among groups (P<0. 001). The ex-pression level of MUC4 was associated with neural invasion ( P=0. 028) , lymph node metastasis ( P=0. 020) and CA19-9 level ( P=0. 028) in PDAC. The median overall survival(OS) of PDAC patients was 17. 0 months(95%CI:14. 809-19. 191 months);The median OS of MUC4 high expression group ( immunohistochemical score≥8. 8) and low expression group ( immunohistochemical score <8. 8) were 13. 0 months ( 95%CI:7. 456-18. 544 months) and 20. 0 months ( 95%CI:15. 521-24. 479 months) , with statistic significance ( P=0. 003) . Conclusion MUC4 perhaps participates in the PDAC occurrence and development. MUC4 expression may be an early event in the evolution of PDAC. MUC4 high expression probably affects both invasion and metastasis of PDAC, and probably predicts poor prognosis.